Background Staphylococcus aureus (S. aureus) bacteremia (SAB) has high morbidity and mortality, with the development of methicillin-resistant S. aureus (MRSA) and the recognized shortcomings of vancom
BackgroundStaphylococcus aureus (S. aureus) bacteremia (SAB) has high morbidity and mortality, with the development of methicillin-resistant S. aureus (MRSA) and the recognized shortcomings of vancomy
1Excludes 15/593 patients known to have been treated but information missing on antibiotics received (n = 10) or susceptibility to methicillin (n = 5, all received flucloxacillin).2Of 578 with informa
Patients are categorised according to first week antimicrobial therapy into anti-staphylococcal penicillin or cephalosporin. Values are n (%). NS = non-significant.
Patients with alcoholism, acute or chronic liver diseases, lack of deep infection foci, MRSA bacteraemia (n = 6) or a fatal outcome within 3 days have been excluded. Values are expressed as n (%). NS